Singapore HSA Launches Innovation Office to Support Product Development 

As part of the aim to facilitate the efficient development and timely registration of beneficial innovative therapeutic products (chemical and biologic compounds) and cell, tissue or gene therapy products (CTGTPs) in Singapore, HSA have set up an Innovation Office on 1st March 2021 as a pilot to provide a conducive regulatory environment that will also support the development of the biomedical sector.  

Based on the pilot, refinements may be made to further improve process efficiency, and to better meet stakeholder needs. 

The Innovation Office provides scientific and regulatory advice to researchers, academia, biotechs, and pharmaceutical companies with an interest in early stage clinical product development, and with the intent to pursue product registration in Singapore.  

This office will work closely with researchers across public sector research agencies and the biotech-pharma industry to offer regulatory support to facilitate the translation of scientific discoveries into clinical treatments that are beneficial to patients in Singapore. 

The Innovation Office enables individuals, researchers or companies to proactively engage with HSA on regulatory requirements, and seek early guidance on technical or scientific issues that need to be considered during product development. 

You can e-mail the Innovation Office on queries or requests to meet, in relation to innovative therapeutic products. 

More details are found on the Singapore HSA website: 

Share on Linkedin Send to Email

Questions? Request more information from our specialists!

Contact Us

More News